All In Biotech

Drugs by condition

Drugs approved for geographic atrophy

Brand-name prescription drugs and biologics whose FDA label lists geographic atrophy as an approved use. Matched on the label phrases: "geographic atrophy".

Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

2

Still marketed, NDA or BLA

Drug classes

2

Novel drugs

1

New molecular entities and new biologics

In development

21

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for geographic atrophy.

  • Izervay (Avacincaptad Pegol Sodium) · Astellas NovelBreakthrough therapyPriority reviewAug 4, 2023
  • Syfovre (Pegcetacoplan) · Apellis Pharms Priority reviewFeb 17, 2023

All approved drugs for geographic atrophy, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 0 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Complement Inhibitor (1)

  • Syfovre Pegcetacoplan · Apellis Pharms · 2023

Class not listed in FDA's data (1)

  • Izervay Avacincaptad Pegol Sodium · Astellas · 2023

Drugs in development for geographic atrophy

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • siRNAADX-038, ADX-324Phase 37 trials

    ADARx Pharmaceuticals, Inc. · Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1

  • CemdisiranALN-CC5Phase 35 trials

    Regeneron · Paroxysmal Nocturnal Hemoglobinuria, Generalized Myasthenia Gravis, Age-related Macular Degeneration (AMD)

  • TinlarebantLBS-008Phase 33 trials

    Belite Bio, Inc · Stargardt Disease 1, STGD1, Geographic Atrophy

  • JNJ-81201887AAVCAGsCD59Phase 32 trials

    Johnson & Johnson (Janssen) · Geographic Atrophy, Macular Degeneration

  • VonaprumentANX007Phase 32 trials

    Annexon, Inc. · Geographic Atrophy

  • BS01Phase 22 trials

    Bionic Sight LLC · Retinitis Pigmentosa, Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)

  • OpRegenPhase 22 trials

    Roche (Genentech) · Age-Related Macular Degeneration, Geographic Atrophy

  • STL303Phase 22 trials

    Sitala Bio LTD · IgAN, Geographic Atrophy

  • ABBV-6628Phase 21 trial

    AbbVie · Geographic Atrophy, Age-Related Macular Degeneration

  • APL-3007Phase 21 trial

    Apellis Pharmaceuticals, Inc. · Geographic Atrophy Secondary to Age-related Macular Degeneration

  • AVD-104Phase 21 trial

    Aviceda Therapeutics, Inc. · Geographic Atrophy of the Macula, Macular Degeneration

  • BI 1584862Phase 21 trial

    Boehringer Ingelheim · Geographic Atrophy

  • BI 771716Phase 21 trial

    Boehringer Ingelheim · Macular Degeneration, Age-related, Geographic Atrophy

  • BRX011Phase 21 trial

    Biojiva LLC · Geographic Atrophy

  • FWY003Phase 21 trial

    Novartis · Geographic Atrophy Secondary to Age-related Macular Degeneration

  • GAL-101Phase 21 trial

    Galimedix Therapeutics Inc · Geographic Atrophy of the Macula

  • PST-611Phase 21 trial

    Eyevensys · Geographic Atrophy, Age - Related Macular Degeneration (AMD)

  • RO7965032Phase 21 trial

    Roche (Genentech) · Geographic Atrophy Secondary to Age-Related Macular Degeneration

  • SAR446597Phase 21 trial

    Sanofi · Geographic Atrophy

  • SOM-401Phase 21 trial

    Inflammasome Therapeutics · Geographic Atrophy, Age-Related Macular Degeneration

More on geographic atrophy: recruiting trials · published research

Related in ophthalmology: Wet macular degeneration · Diabetic macular edema · Glaucoma · Dry eye disease

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.